| Literature DB >> 34975740 |
Anna Fetta1,2, Veronica Di Pisa1, Martina Ruscelli2, Luca Soliani1,2, Giacomo Sperti3, Sara Ubertiello1, Emilia Ricci4, Greta Mainieri5, Alessandro Rocca6, Maria Margherita Mancardi7, Lucio Giordano8, Dario Pruna9, Aglaia Vignoli10, Federica Provini5,11, Duccio Maria Cordelli1,2.
Abstract
Objectives: Pallister-Killian syndrome (PKS) is a rare genetic disorder with multi-organ involvement caused by mosaic tetrasomy of chromosome 12p. Although many caregivers report the presence of impaired sleep in their children, there are no clear data in the literature on this issue and no systematic study has ever been performed. With this study, we aimed to characterize the features of sleep in Pallister-Killian syndrome and identify the possible influence of clinical and demographic features. Moreover, our aim was to verify the effectiveness of conventional screening questionnaires in this particular group of patients.Entities:
Keywords: PKS; SDSC; rare disease; sleep disorders; video polysomnography
Year: 2021 PMID: 34975740 PMCID: PMC8716439 DOI: 10.3389/fneur.2021.796828
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Demographic and clinical features, and SDSC results.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. 1 | F | 1y | Yes | No therapy | – | 41 | 51 | 47 | 50 | 46 | 51 | 45 |
| No. 2 | F | 1y | No | – | – | 60 | 45 | 47 | 75 | 42 | 69 | 62 |
| No. 3 | F | 1y, 5m | No | – | – | 64 | 51 | 47 | 66 | 64 | 45 | 64 |
| No. 4 | M | 1y, 5m | No | – | – | 73 | 86 | 47 | 41 | 64 | 64 | 70 |
| No. 5 | M | 2y, 4m | Yes | VGB, VPA | Melatonin | 79 | 100 | 70 | 84 | 81 | 69 | 99 |
| No. 6 | F | 6y | No | – | Melatonin | 66 | 100 | 94 | 100 | 69 | 69 | 100 |
| No. 7 | M | 7y, 3m | Yes | CBZ | – | 70 | 100 | 100 | 75 | 73 | 45 | 90 |
| No. 8 | F | 11y 6m | Yes | VPA | – | 60 | 45 | 70 | 58 | 88 | 45 | 69 |
| No. 9 | F | 11y, 10m | No | N/A | – | 60 | 45 | 70 | 41 | 50 | 45 | 51 |
| No. 10 | F | 12y, 1m | Yes | CBZ | – | 70 | 86 | 47 | 41 | 53 | 45 | 62 |
| No. 11 | F | 13y, 7m | Yes | VPA, CBZ | – | 64 | 58 | 58 | 79 | 58 | 45 | 68 |
| No. 12 | M | 14y, 4m | No | – | – | 66 | 58 | 70 | 58 | 50 | 45 | 62 |
| No. 13 | M | 16y, 4m | Yes | PB, LEV, VGB, CBZ | – | 100 | 100 | 70 | 41 | 77 | 69 | 100 |
| No. 14 | M | 17y, 4m | Yes | LEV, CBZ | Melatonin | 73 | 86 | 47 | 50 | 42 | 45 | 62 |
| MEDIAN (IQR) | 66 (11.25) | 72 (45.5) | 64 (23) | 58 (31.75) | 61 (22) | 45 (22.75) | 66 (23) |
AED, anti–epileptic drugs; VPA, valproic acid; VGB, vigabatrin; CBZ, carbamazepine; PB, phenobarbital; LEV, levetiracetam. For all patients, the melatonin dosage ranged from 2 to 5 mg.
VPSG data of PKS children compared with controls of all ages.
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| TIB (min) | 659.50 | 103.00 | 563.5 | 67.5 | 0.0041 |
| SPT (min) | 646.00 | 115.25 | 545 | 62.75 | 0.008 |
| TST (min) | 542.50 | 141.50 | 522.5 | 86.25 | 0.4286 |
| SEI (%) | 81.85 | 25.27 | 94.3 | 4.25 | 0.0006 |
| SOL (min) | 8.40 | 21.30 | 8.6 | 3.375 | 0.4364 |
| FRL (min) | 70.50 | 62.62 | 75.5 | 59.15 | 0.4443 |
| WASO (%SPT) | 13.85 | 24.05 | 2.35 | 4.825 | 0.0011 |
| N1 (%TST) | 7.30 | 4.35 | 4.15 | 2.725 | 0.007 |
| N2 (%TST) | 40.50 | 11.57 | 52.8 | 9.125 | 0.0005 |
| N3 (%TST) | 32.50 | 9.93 | 16.2 | 4.025 | <0.00001 |
| REM (%TST) | 19.20 | 6.57 | 27.25 | 5.575 | 0.0004 |
| AI (n/h TST) | 12.7 | 11.35 | 4.4 | 2.1125 | <0.00001 |
| AWI (n/h SPT) | 0.95 | 0.65 | 0.81 | 0.9875 | 0.1788 |
IQR, interquartile range; TIB, time in bed; SPT, sleep period time; TST, total sleep time; SEI, sleep efficiency index; SOL, sleep onset latency; FRL, first REM latency; WASO, wakefulness after sleep onset; AI, arousal index; AWI, awakenings index.
p < 0.05.
VPSG data of subgroup A (1–7 y) compared with control subgroup Ac (1–10 y).
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| TIB (min) | 679 | 148.5 | 573 | 36 | 0.0630 |
| SPT (min) | 672 | 176.5 | 550 | 26.5 | 0.0793 |
| TST (min) | 460 | 135.5 | 527 | 57.5 | 0.2611 |
| SEI (%) | 79.9 | 19.8 | 95.2 | 1 | 0.0025 |
| SOL (min) | 9.2 | 15.45 | 9.7 | 2.9 | 0.1762 |
| FRL (min) | 99.5 | 75.5 | 63 | 74.25 | 0.2843 |
| WASO (%SPT) | 19.2 | 24.55 | 1.3 | 1.35 | 0.0025 |
| N1 (%TST) | 10.6 | 7.1 | 4 | 5 | 0.015 |
| N2 (%TST) | 36 | 8.5 | 54.9 | 10 | 0.0052 |
| N3 (%TST) | 27.3 | 9.5 | 16.2 | 2.45 | 0.0011 |
| REM (%TST) | 20.2 | 10.95 | 28.1 | 5.15 | 0.015 |
| AI (n/h TST) | 17.7 | 10.3 | 5.5 | 2.25 | 0.0011 |
| AWI (n/h SPT) | 1 | 0.9 | 0.32 | 0.49 | 0.0207 |
IQR, interquartile range; TIB, time in bed; SPT, sleep period time; TST, total sleep time; SEI, sleep efficiency index; SOL, sleep onset latency; FRL, first REM latency; WASO, wakefulness after sleep onset; AI, arousal index; AWI, awakenings index.
p < 0.05.
VPSG data of subgroup B (11–17 y) compared with control subgroup Bc (11–16 y).
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| TIB (min) | 636 | 70 | 526 | 120.5 | 0.0485 |
| SPT (min) | 633 | 79.5 | 514 | 110 | 0.7927 |
| TST (min) | 545 | 60.5 | 476 | 106 | 0.2207 |
| SEI (%) | 89 | 15.95 | 91.1 | 1.7 | 0.0207 |
| SOL (min) | 7.6 | 21.05 | 8.3 | 4.4 | 0.4483 |
| FRL (min) | 69.5 | 30.75 | 76 | 15.55 | 0.1251 |
| WASO (%SPT) | 9 | 15.55 | 6.1 | 2.75 | 0.0630 |
| N1 (%TST) | 6.4 | 3.35 | 4.3 | 0.85 | 0.1867 |
| N2 (%TST) | 41.8 | 10.3 | 52.7 | 5.05 | 0.0207 |
| N3 (%TST) | 35 | 10.45 | 15.2 | 5.2 | 0.0011 |
| REM (%TST) | 18.2 | 4.8 | 26.4 | 4.9 | 0.0107 |
| AI (n/h TST) | 12.1 | 5.85 | 4.08 | 1.65 | 0.0011 |
| AWI (n/h SPT) | 0.9 | 0.55 | 0.86 | 1.19 | 0.3264 |
IQR, interquartile range; TIB, time in bed; SPT, sleep period time; TST, total sleep time; SEI, sleep efficiency index; SOL, sleep onset latency; FRL, first REM latency; WASO, wakefulness after sleep onset; AI, arousal index; AWI, awakenings index.
p < 0.05.
Figure 1The respiratory events in the 10 PKS subjects evaluated are shown, divided by type of respiratory event. RERA, respiratory effort-related arousal.
Figure 2The graphic shows the direct linear correlation between the sleep breathing disorders (SBD) subscale in SDSC test and Apnea-Hypopnea Index (AHI). Pearson's r = 0.80; p = 0.005.